|
Activity Number:
|
385
|
|
Type:
|
Contributed
|
|
Date/Time:
|
Wednesday, August 9, 2006 : 8:30 AM to 10:20 AM
|
|
Sponsor:
|
Section on Bayesian Statistical Science
|
| Abstract - #307534 |
|
Title:
|
Dose-Schedule Finding in Phase I/II Clinical Trials Using Bayesian Isotonic Transformation
|
|
Author(s):
|
Yisheng Li*+ and Nebiyou B. Bekele and Yuan Ji and John Cook
|
|
Companies:
|
M. D. Anderson Cancer Center and M. D. Anderson Cancer Center and M. D. Anderson Cancer Center and M. D. Anderson Cancer Center
|
|
Address:
|
1515 Holcombe Blvd., Unit 447, Houston, TX, 77030,
|
|
Keywords:
|
dose-schedule finding ; clinical trial ; Bayesian design ; phase I/II ; isotonic transformation ; partially-ordered constraints
|
|
Abstract:
|
Most phase I oncology trials aim to locate the MTD of an experimental treatment. One of the main considerations apart from determining the MTD is determining an appropriate schedule for administration of the treatment. Historically, schedules have been fixed prior to the start of dose finding. Recently, an increasing number of trials have been designed to determine a dose AND a schedule. We propose a Bayesian design for dose-schedule finding by jointly modeling the binary toxicity and efficacy outcomes. Assuming ordered toxicity probabilities between schedules, we apply an isotonic transformation approach to estimating the constrained parameters. We select dose-schedule combination based on the joint posterior distribution of efficacy and toxicity. Using a simulation study and a real cancer clinical trial, we examine the operating characteristics of the proposed design.
|
